POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2

Abstract

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.

CPC Classifications